In assessing the safety of drugs, “every bit of information is helpful,” said Dr. Mark Lebwohl, president of the American Academy of Dermatology, in email to Reuters Health. “Data from randomized, controlled clinical trials, large registries, postmarketing surveillance, retrospective chart reviews, and many other sources add to the body of knowledge that tells us if a drug is safe.”
Dr. Yeung has been a speaker, consultant, and investigator for Abbvie, Amgen, and Janssen, all of which make psoriasis drugs.
